The Ministry of Health and Community Protection has confirmed that so far there is no international or local decision to stop the use of ranitidine, commercially known as Zantac, and that it is being verified by international health authorities to assess whether low levels of NDMA in ranitidine pose a risk to The patients.
The ministry told Emirates Today that international authorities do not recommend stopping the product, and patients who wish to stop use should talk to a health care professional about other treatment options.
She said she would take appropriate action once the results of international investigations into the drug were released.
This came after news spread about the announcement of the US Food and Drug Administration (FDA) that it has concluded that some drugs rantidine, including the drug known commercially «Zantak», which is used to treat acidity and stomach ulcers, contain low levels of carcinogenic impurities nitrosamine, which provoked A wave of fear among drug users worldwide.